CYTOTOXICITY OF INTERLEUKIN-2-ACTIVATED LYMPHOCYTES FOR LEUKEMIA AND LYMPHOMA-CELLS
- 1 October 1986
- journal article
- research article
- Vol. 68 (4), 938-948
Abstract
Studies were undertaken to determine whether leukemia and lymphoma cells would be lysed by autologous and allogeneic lymphokine-activated killer (LAK) cells. Peripheral blood mononuclear cells (PBMC) from patients and normal donors were cultured for five days, 2 weeks, and 4 weeks with medium containing 2,500 units of recombinant interleukin 2 (IL-2) per mL, and their cytotoxicity was assayed by a five-hour 51Cr-release test. Of primary tumors isolated from patients with acute nonlymphoblastic leukemia, acute lymphoblastic leukemia, and non-Hodgkin''s lymphoma, tumors of 37 out of 40 patients tested were shown to be susceptible to normal donors'' LAK, and tumors of 18 of 20 patients tested were shown to be susceptible to autologous LAK. LAK cultured for longer periods showed a tendency to have lower cytotoxicity. LAK had also low, but significant, levels of cytotoxicity for nonmalignant target cells. Because PBMC expanded in IL-2-containing medium consisted mainly of OKT3-positive pan T cells, OKT8-positive suppressor/cytotoxic cells, and Leu-11-positive natural killer (NK) cells, and treatment with OKT3 and Leu-11 monoclonal antibodies (mAb) reduced LAK activity for autologous and allogeneic tumor cells, both T and NK cells appeared to be effector cells for LAK activity. Mechanisms of target-cell recognition in the LAK system seem to be different from those in alloreactive cytotoxic T lymphocytes (CTL) based on the results that, while cytotoxicity of alloreactive CTL was inhibited by the treatment of effector cells with mAb, OKT3, OKT8, and by the treatment of target cells with a mAb that reacts with HLA class l antigen, LAK activity was not inhibited by the above treatment. When chromosomes of IL-2-expanded PBMC in nine patients and two normal individuals were analyzed, PBMC from one patient showed chromosomes of clonal abnormalities, and PBMC from five donors showed those of nonclonal abnormalities.This publication has 43 references indexed in Scilit:
- A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells.The Journal of Immunology, 1981
- HUMAN LYMPHOCYTE-T GROWTH-FACTOR - REGULATION OF GROWTH AND FUNCTION OF LYMPHOCYTES-T1981
- INVITRO GROWTH OF CYTO-TOXIC HUMAN-LYMPHOCYTES .4. LYSIS OF FRESH AND CULTURED AUTOLOGOUS TUMOR BY HUMAN-LYMPHOCYTES CULTURED IN T-CELL GROWTH-FACTOR1981
- Cytotoxicity of Cultured Mouse Spleen Cells against Natural Killer-Sensitive Target CellsInternational Archives of Allergy and Immunology, 1981
- Ia determinants on human T-cell subsets defined by monoclonal antibody. Activation stimuli required for expression.The Journal of Experimental Medicine, 1979
- T Cell Growth Factor: Parameters of Production and a Quantitative Microassay for ActivityThe Journal of Immunology, 1978
- Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysisCell, 1978
- STUDIES ON CYTOTOXICITY GENERATED IN HUMAN MIXED LYMPHOCYTE-CULTURES .1. TIME COURSE AND TARGET SPECTRUM OF SEVERAL DISTINCT CONCOMITANT CYTOTOXIC ACTIVITIES1978
- Selective in Vitro Growth of T Lymphocytes from Normal Human Bone MarrowsScience, 1976
- Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative GroupBritish Journal of Haematology, 1976